Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Abstract

BACKGROUND:

Morning hypertension is a risk factor for cardiovascular and cerebrovascular events, and consequently diagnosis and control of morning hypertension are considered very important. We previously reported the results of the Azelnidipine Treatment for Hypertension Open-label Monitoring in the Early morning (At-HOME) Study, which indicated that azelnidipine effectively controlled morning hypertension.

OBJECTIVES:

The objective of this At-HOME subgroup analysis was to evaluate the sustained blood pressure (BP)-lowering effect of azelnidipine, using mean morning and evening systolic BP [ME average] and morning systolic BP minus evening systolic BP (ME difference).

METHODS:

We analyzed the self-measured home BP data (measured in the morning and at bedtime) from this 16-week prospective observational study to clarify the effect of morning dosing of azelnidipine (mean [± standard deviation] maximum dose 14.3 ± 3.6 mg/day). A subgroup of patients from the At-HOME Study who had an evening home BP measurement within 28 days prior to the baseline date were used for efficacy analysis (n = 2,546; mean age, 65.1 years; female, 53.6 %).

RESULTS:

Home systolic BP/diastolic BP levels in the morning and evening were significantly lowered (p < 0.0001) by -19.4 ± 17.1/-10.3 ± 10.6 and -16.9 ± 17.0/-9.4 ± 10.6 mmHg, respectively. Home pulse rates in the morning and evening were also significantly lowered (p < 0.0001) by -3.5 ± 7.8 and -3.5 ± 7.3 beats/min, respectively. At baseline, patients whose ME average was ≥135 mmHg and whose ME difference was ≥15 mmHg (defined as morning-predominant hypertension) accounted for 20.4 % of the study population. However, at the end of the study, the number of such patients was significantly reduced to 7.9 % (p < 0.0001). Patients whose ME average was ≥135 mmHg and whose ME difference was <15 mmHg (defined as sustained hypertension) accounted for 71.1 % of the study population at baseline. This was reduced significantly to 42.8 % at the end of the study (p < 0.0001). ME average decreased significantly from 153.8 ± 15.5 mmHg to 135.6 ± 11.9 mmHg, and ME difference also decreased significantly from 6.7 ± 13.1 mmHg to 4.7 ± 10.8 mmHg (both p < 0.0001).

CONCLUSION:

These results suggest that azelnidipine improved morning hypertension with its sustained BP-lowering effect.

• Authors: Kazuomi Kario, Yoko Uehara, Masayuki Shirayama, Megumi Takahashi, Kazuhito Shiosakai, Katsutoshi Hiramatsu, Masahiro Komiya, Kazuyuki Shimada
• Journal: Drugs in R&D (Drugs R D) Vol. 13 Issue 1 Pg. 75-85 (Mar 2013) ISSN: 1179-6901 [Electronic] New Zealand
• PMID: 23519655 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Dihydropyridines
• Azetidinecarboxylic Acid
• azelnidipine

Topics

• Adolescent
• Adult
• Aged
• Antihypertensive Agents (pharmacology, therapeutic use)
• Azetidinecarboxylic Acid (analogs & derivatives, pharmacology, therapeutic use)
• Blood Pressure (drug effects, physiology)
• Blood Pressure Monitoring, Ambulatory (methods, standards)
• Circadian Rhythm (drug effects, physiology)
• Dihydropyridines (pharmacology, therapeutic use)
• Female
• Humans
• Hypertension (drug therapy, epidemiology, physiopathology)
• Male
• Middle Aged
• Prospective Studies
• Time Factors
• Treatment Outcome
• Young Adult